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OBJECTIVE: To compare subjective response and com-
pliance of olanzapine-treated patients and patients treated
with other antipsychotics in an observational prospective
study (EFESO). METHODS: Outpatients entered the
study when they received a new prescription of an antip-
sychotic drug. Patients treated with olanzapine (n 
2128), risperidone (n  417) and haloperidol (n  112)
were included in the analysis. Subjective response was
measured using the 10-item version of the Drug Attitude
Inventory (DAI-10). Treatment compliance was mea-
sured using a physician-rated 4 point categorical scale.
Subjective response and compliance were compared be-
tween the treatment groups. Data were collected at base-
line and after 3 and 6 months. RESULTS: Overall mean
doses were respectively 13 mg, 5.4 mg and 13.6 mg for
olanzapine, risperidone and haloperidol treated patients.
All three groups had a positive subjective response to
treatment. Olanzapine treated patients had significantly
higher DAI-10 score compared to both risperidone and
haloperidol treated patients at 3 months (P  0.003 and
P  0.001 respectively) and at 6 months (P  0.001 vs
risperidone and haloperidol). Risperidone-treated patients
had a higher DAI-10 score compared to haloperidol-
treated patients at both 3 months and 6 months (P  0.003).
Olanzapine-treated patients had significantly better treat-
ment compliance compared to both risperidone and halo-
peridol treated patients at 6 months (P  0.001 and P 
0.022 respectively). CONCLUSION: Despite the limita-
tions of an observational study, these results suggest that
in routine clinical practice, olanzapine-treated patients
exhibit a superior subjective response and compliance
compared to risperidone and haloperidol treated patients.
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OBJECTIVE: A model was developed to assess the clinical
outcome and costs of an intensive deinstitutionalization
strategy called Intensive Case Management (ICM) in com-
parison to Standard Case Management (SCM) for persons
suffering of chronic schizophrenia and long term hospital-
ized (1 year). METHODS: A Markov Model was con-
structed to describe the different possibilities of case man-
agement of long term hospitalized schizophrenic patients.
The Markov states were classified to one of five categories
hospital, institution, outpatient, dropout, and death, fol-
lowed by either success or failure of the adopted case man-
agement. Clinical, functioning improvement, and patient
discharge from acute care unit define success here. The
Markov process iterates in 1-year cycles until the 5-year.
Model probabilities are gathered from an ongoing ambi-
spective cohort of patients assigned to ICM or SCM in the
catchment area of Clermont-Ferrand. Control patients
(SCM) were/are retrospectively chosen on the premise that
they could have been selected for ICM group. Service utili-
zation data are obtained from patient medical and adminis-
trative record while direct costs are obtained from the ana-
lytical accounting system of the catchment area. RESULTS:
Based on the primary data collected (ICM: n  42, SCM:
n  28), the outcomes of the two types of care showed,
that the ICM was more effective in terms of success over
the first one-year period 59% of the patients experienced a
success as opposed to 25% in SCM. It was also shown that
readmission to hospital was more likely in the SCM (67%
as opposed to 22% in ICM). A threshold analysis will be
performed in order to evaluate at which point ICM will
be too costly for the hospital budget. CONCLUSIONS:
With these outcome results, ICM is shown to be more ef-
fective than SCM. The model will be used to generate cost-
effectiveness ratios, budgetary previsions for large-scale im-
plementation of ICM, in order to help decision-makers in
policy-making for mental health care organizations.
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OBJECTIVE: To assess the concordance of self reports,
parental reports and urine drug bioassays as measures of
drug use in adolescents treated for chemical dependency.
Questions addressed are, (1) what is the concordance be-
tween self reports, parental reports and bioassays? (2)
does the concordance vary over time? METHODS: Anal-
yses are based on panel study data from 119 adolescents
and their parents. Each adolescent completed drug treat-
ment at the same facility in the same time period. To as-
sess treatment effectiveness adolescents and their parents
were followed prospectively and interviewed separately
with a standardized questionnaire at 3, 6, 9 and 12 months
post treatment. Random urine bioassays via enzyme im-
munoassay were administered during the study. Each ad-
olescent was drug tested a minimum of 9 times. RESULTS:
Eighty-one percent of the adolescents self-reported sub-
stance use during the study period and 31% had a posi-
tive urine bioassays (Cohen’s Kappa 	  .077, P  .388).
Sixty-five percent reported using alcohol while there were
no bioassays positive for alcohol. The concordance be-
tween reported marijuana use and positive urine bioas-
says showed that 48% reported using marijuana while
29% had a positive marijuana bioassay (	  .40, P 
.006). Fifty-two percent reported using several different
substances but had as many as ten negative drug screens.
Sixty four percent of the parents of the adolescents who
reported use confirmed that their child used in the first
